<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Paré, Guillaume</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CURE ACTIVE: No Loss of Clopidogrel Efficacy with the CYP2C19 Loss-of-Function Allele in Patients with ACS or AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-34</style></pages><abstract><style  face="normal" font="default" size="100%">Genetic variations that are related to clopidogrel metabolism did not diminish clopidogrel efficacy in patients with acute coronary syndromes or atrial fibrillation, according to new data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events [CURE] and Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE] trials.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>